Suppr超能文献

核糖体S6激酶的缺失并不会减弱病理性、生理性或胰岛素样生长因子1受体-磷酸肌醇3激酶诱导的心脏肥大。

Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy.

作者信息

McMullen Julie R, Shioi Tetsuo, Zhang Li, Tarnavski Oleg, Sherwood Megan C, Dorfman Adam L, Longnus Sarah, Pende Mario, Martin Kathleen A, Blenis John, Thomas George, Izumo Seigo

机构信息

Beth Israel Deaconess Medical Center, Cardiovascular Division, 330 Brookline Ave., SL-408, Boston, MA 02215, USA.

出版信息

Mol Cell Biol. 2004 Jul;24(14):6231-40. doi: 10.1128/MCB.24.14.6231-6240.2004.

Abstract

Ribosomal S6 kinases (S6Ks) have been depicted as critical effectors downstream of growth factor pathways, which play an important role in the regulation of protein synthesis by phosphorylating the ribosomal protein, S6. The goal of this study was to determine whether S6Ks regulate heart size, are critical for the induction of cardiac hypertrophy in response to a pathological or physiological stimulus, and whether S6Ks are critical downstream effectors of the insulin-like growth factor 1 (IGF1)-phosphoinositide 3-kinase (PI3K) pathway. For this purpose, we generated and characterized cardiac-specific S6K1 and S6K2 transgenic mice and subjected S6K1(-/-), S6K2(-/-), and S6K1(-/-) S6K2(-/-) mice to a pathological stress (aortic banding) or a physiological stress (exercise training). To determine the genetic relationship between S6Ks and the IGF1-PI3K pathway, S6K transgenic and knockout mice were crossed with cardiac-specific transgenic mice overexpressing the IGF1 receptor (IGF1R) or PI3K mutants. Here we show that overexpression of S6K1 induced a modest degree of hypertrophy, whereas overexpression of S6K2 resulted in no obvious cardiac phenotype. Unexpectedly, deletion of S6K1 and S6K2 had no impact on the development of pathological, physiological, or IGF1R-PI3K-induced cardiac hypertrophy. These studies suggest that S6Ks alone are not essential for the development of cardiac hypertrophy.

摘要

核糖体S6激酶(S6Ks)被描述为生长因子信号通路下游的关键效应分子,其通过磷酸化核糖体蛋白S6在蛋白质合成调控中发挥重要作用。本研究的目的是确定S6Ks是否调节心脏大小,是否是响应病理或生理刺激诱导心肌肥大的关键因素,以及S6Ks是否是胰岛素样生长因子1(IGF1)-磷酸肌醇3激酶(PI3K)信号通路的关键下游效应分子。为此,我们构建并鉴定了心脏特异性S6K1和S6K2转基因小鼠,并使S6K1(-/-)、S6K2(-/-)和S6K1(-/-)S6K2(-/-)小鼠遭受病理应激(主动脉缩窄)或生理应激(运动训练)。为了确定S6Ks与IGF1-PI3K信号通路之间的遗传关系,将S6K转基因和敲除小鼠与过表达IGF1受体(IGF1R)或PI3K突变体的心脏特异性转基因小鼠进行杂交。我们发现,S6K1的过表达诱导了适度的肥大,而S6K2的过表达未导致明显的心脏表型。出乎意料的是,S6K1和S6K2的缺失对病理、生理或IGF1R-PI3K诱导的心肌肥大的发展没有影响。这些研究表明,单独的S6Ks对心肌肥大的发展并非必不可少。

相似文献

6
FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K.
Am J Physiol Heart Circ Physiol. 2021 Apr 1;320(4):H1470-H1485. doi: 10.1152/ajpheart.00838.2020. Epub 2021 Feb 12.
9
Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway.
J Biol Chem. 2001 Mar 16;276(11):7884-91. doi: 10.1074/jbc.M006969200. Epub 2000 Dec 6.

引用本文的文献

1
Hyperactive mTORC1/4EBP1 signaling dysregulates proteostasis and accelerates cardiac aging.
Geroscience. 2025 Apr;47(2):1823-1836. doi: 10.1007/s11357-024-01368-w. Epub 2024 Oct 9.
3
Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development.
Rev Cardiovasc Med. 2022 May 6;23(5):165. doi: 10.31083/j.rcm2305165. eCollection 2022 May.
4
Role and targeting of the AGC kinase family in pulmonary fibrosis (Review).
Exp Ther Med. 2024 Mar 8;27(5):190. doi: 10.3892/etm.2024.12478. eCollection 2024 May.
5
Sports activities and cardiovascular system change.
Physiol Res. 2023 Dec 29;72(S5):S429-S444. doi: 10.33549/physiolres.935238.
6
The mTOR signaling pathway in cardiac aging.
J Cardiovasc Aging. 2023;3(3). doi: 10.20517/jca.2023.10. Epub 2023 May 4.
7
Nutrient-regulated dynamics of chondroprogenitors in the postnatal murine growth plate.
Bone Res. 2023 Apr 21;11(1):20. doi: 10.1038/s41413-023-00258-9.
9
Beyond controlling cell size: functional analyses of S6K in tumorigenesis.
Cell Death Dis. 2022 Jul 25;13(7):646. doi: 10.1038/s41419-022-05081-4.
10
NAP1L5 Promotes Nucleolar Hypertrophy and Is Required for Translation Activation During Cardiomyocyte Hypertrophy.
Front Cardiovasc Med. 2021 Dec 17;8:791501. doi: 10.3389/fcvm.2021.791501. eCollection 2021.

本文引用的文献

1
Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload.
Circulation. 2004 Jun 22;109(24):3050-5. doi: 10.1161/01.CIR.0000130641.08705.45. Epub 2004 Jun 7.
3
mTOR-mediated regulation of translation factors by amino acids.
Biochem Biophys Res Commun. 2004 Jan 9;313(2):429-36. doi: 10.1016/j.bbrc.2003.07.015.
6
Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy.
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12355-60. doi: 10.1073/pnas.1934654100. Epub 2003 Sep 24.
7
Rapamycin attenuates load-induced cardiac hypertrophy in mice.
Circulation. 2003 Apr 1;107(12):1664-70. doi: 10.1161/01.CIR.0000057979.36322.88. Epub 2003 Mar 17.
10
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E.
Genes Dev. 2002 Jun 15;16(12):1472-87. doi: 10.1101/gad.995802.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验